The American College of Rheumatology (ACR) has included the Vectra test from Myriad Genetics, Salt Lake City, among its latest recommendations about disease activity measurement systems for patients with rheumatoid arthritis (RA).1

The recommendations list the Vectra test among 11 disease activity measurement systems that met a minimum standard by categorizing test findings into disease activity states and being feasible for regular clinical use. Among 46 systems evaluated by ACR, Vectra was one of the five most frequently studied RA disease activity measurement systems. There are currently more than 35 peer-reviewed journal articles that include study data about the Vectra test.

Hitraya

Elena Hitraya, MD, Myriad Autoimmune.

“We are excited that the Vectra test has been included in the ACR’s recommendations for disease activity measures. It will provide physicians with an additional option to evaluate their patients with RA,” says Elena Hitraya, MD, PhD, chief medical officer at Myriad Autoimmune. “Vectra objectively measures the inflammation associated with RA and can provide valuable information to help clinicians improve treatment decisions and outcomes for patients with RA.”

RA is an autoimmune disease that attacks the patient’s joints and often affects other organ systems, leading to significant morbidity, increased mortality, and financial burden. Approximately 60% of people with inadequately treated RA are unable to work within a decade after its onset. ACR estimates that RA affects 1.5 million people in the United States.

For more information, visit Myriad Genetics.

Reference

  1. England BR, Tiong BK, Bergman MJ, et al. 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 2019;71(12):1540–1555; doi: 10.1002/acr.24042.

Featured image:

 Rheumatoid arthritis. X-rays of both hands of a child with multiple joint arthritis. Photo © Puwadol Jaturawutthichai, courtesy Dreamstime (ID 60390002).